tiprankstipranks
Analyst Profile
Followed by 81 other investors
.
David Steinberg

David Steinberg

Jefferies
Wall Street Analyst
Ranked #1,052 out of 8,045 Analysts on TipRanks (#1,791 out of 21,519 overall experts)

Success Rate

49%
175 out of 356 Profitable Transactions

Average Return

7.70%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied David Steinberg's ratings since 2012 and opened each position for the duration of 1 Year:
49.16% of your transactions would have been profitable with an average return of 7.7%

Stock Rating Distribution

550Ratings
86.73% Buy
13.09% Hold
0.18% Sell
Distribution of David Steinberg's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market
United KingdomUK Market

Best Rating

Stock:
Nektar Therapeutics
(NKTR)
Rating Type:Buy
Dates:Mar 02, 2017 - Mar 02, 2018
Gain:595.50%
The most profitable rating made by David Steinberg

David Steinberg's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
Omeros
Mar 15, 2012
Buy
Upgraded
0%
-46.40%
1
MRX
Medicis Pharmaceutical
Apr 07, 2012
Buy
Reiterated
100%
+12.40%
1
SLXP
Salix
Mar 18, 2015
Hold
Downgraded
100%
+49.20%
6
Novartis
Mar 08, 2016
Buy
Reiterated
$60.50
(-29.14% Downside)
100%
+7.20%
2
Johnson & Johnson
May 16, 2016
Hold
Reiterated
0.00%
2
~ANAC
Anacor Pharmaceuticals
May 16, 2016
Buy
Reiterated
90%
+41.52%
13
GlaxoSmithKline
May 23, 2016
Hold
Reiterated
123,667.50p
(8685.70% Upside)
0.00%
1
UnitedHealth
Jun 30, 2016
Buy
Assigned
$153.00
(-71.91% Downside)
100%
+33.40%
1
Pfizer
Jun 30, 2016
Buy
Assigned
50%
+0.75%
3
ESRX
Express Scripts
Jun 30, 2016
Buy
Assigned
0%
-15.70%
1
List of latest recommendations made by David Steinberg. Click to expand and see David Steinberg's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More